By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Boston Therapeutics, Inc. 

1750 Elm Street, Suite 103

Manchester  New Hampshire  03104  U.S.A.
Phone: 603-935-9799 Fax: 603-685-4784



Company News
Boston Therapeutics, Inc. To Present Findings Of BTI-320 As Therapy For Glycemic Control At 50th Annual Meeting Of European Association For The Study Of Diabetes 9/17/2014 1:24:48 PM
Boston Therapeutics, Inc. To Present At National Investment Banking Conference On September 16, 2014 9/17/2014 1:07:14 PM
Boston Therapeutics, Inc. To Present At Rodman & Renshaw Annual Global Investment Conference On September 10, 2014 9/8/2014 12:36:12 PM
Boston Therapeutics, Inc. Completes Enrollment Of Patients With Type 2 Diabetes In Phase IIb Study On BTI-320 In The U.S. 8/20/2014 10:13:25 AM
Boston Therapeutics, Inc. Appoints Noted Diabetes Specialist Jaime A. Davidson, M.D. To Its Medical Advisory Board 8/18/2014 9:43:22 AM
Boston Therapeutics, Inc. Expands Medical Advisory Board 8/6/2014 11:07:08 AM
Boston Therapeutics, Inc. To Sponsor Symposium At American Chemical Society's Fall National Meeting In San Francisco 8/1/2014 11:14:47 AM
Boston Therapeutics, Inc. Appoints Zbigniew J. Witczak, Ph.D., To Its Scientific Advisory Board 7/29/2014 11:49:39 AM
Boston Therapeutics, Inc. Appoints Benjamin Rivnay, Ph.D. To Chief Scientist 7/9/2014 11:28:56 AM
Boston Therapeutics, Inc. Initiates Phase 2b Study To Assess The Efficacy And Safety Of SUGARDOWN® For Type 2 Diabetes 5/29/2014 10:18:01 AM